A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

THINK Surgical Receives FDA Clearance of 2nd Generation Active Robot: Features Unique Upgrades to the Current System

November 20, 2020

THINK Surgical reports the FDA has cleared the second-generation of the TSolution One Total Knee Application.

THINK Surgical describes the system features as an active robot for total knee replacement, providing fully automated bone preparation, and gives surgeons a choice of implant options. The new system features upgrades to the current system, including an enhanced pre-surgical planning user interface, quick-change tooling, improved surgeon accessories, and advanced bone model generation. The clearance of the second-generation TSolution One Total Knee Application comes approximately one year after THINK’s first-generation active robot was cleared.

“The ongoing evolution of the TSolution One Total Knee Application is a testament to THINK Surgical’s dedication and investment in advancing the use of robot technology in the orthopedic setting,” said Jay Yang, acting CEO, THINK Surgical. “The versatile, open platform provides surgeons with the flexibility of using a variety of implants, while offering hospitals and ambulatory surgery centers a sustainable, high throughput system for their ever-increasing total knee replacement procedures.”

The TSolution One total Knee Application is comprised of TPLAN®, the 3D pre-surgical planning workstation, and TCAT®, the active robot that helps the surgeon execute each patient’s individual preoperative plan with consistent results through fully automated bone preparation. This second-generation robot incorporates several changes to the hardware and software, which significantly enhance the system’s efficiency, flexibility and ease of use while maintaining the precision and innovation that is the hallmark of the TSolution One Total Knee Application system.

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Sachita Shah, Sr. Director, Global Health, Butterfly Network, "Butterfly is proud to continue improving maternal health equity through Phase Two of the largest-scale handheld ultrasound distribution and training ever conducted in Sub-Saharan Africa. South Africa is an emerging market that continues to have disproportionately high rates of maternal mortality and stillbirth. Patients need easier access to antenatal imaging, and clinicians need better capabilities for screening high-risk conditions that lead to disproportionately worse pregnancy outcomes in rural areas in the public sector. Together with CHAI and GUSI, we can tackle this by making ultrasound much more accessible, so high-risk conditions can be identified earlier in care, which is known to improve outcomes.”
The clinical Study will enroll up to 97 patients at up to 12 European investigational sites. Completion of the study is expected this year, and results will support CE mark and pre-market approval submissions reports Vivasure Medical.
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.

By using this website you agree to accept Medical Device News Magazine Privacy Policy